Sugemalimab (CS1001) is a fully humanized, full-length monoclonal antibody targeting PD-L1. It cross-links PD-L1-positive tumor cells with macrophages, inducing antibody-dependent cellular cytotoxicity. Sugemalimab is being studied for EGFR mutation-negative and ALK-negative metastatic non-small cell lung cancer (NSCLC), advanced solid tumors, and lymphoma.
Purity:
95.00%
CAS Number:
[2256084-03-2]
Target:
PD-1/PD-L1
* VAT and and shipping costs not included. Errors and price changes excepted
